Everything below concerns angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-04. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
The secondary stage occurs months to two years later (but usually 1–2 months later), and may thus begin when the mother wound has not yet healed. It happens when the bacterium spreads in the blood and lymph. It begins as multiple, pinhead-like papules; these initial lesions grow and change in appearance and may last weeks before healing, with or without scarring. Secondary yaws typically shows widespread skin lesions that vary in appearance, including "crab yaws" (areas of skin of abnormal color) on the palms of the hands and soles of the feet (named for the crab-like gait they cause people with painful soles to assume). These may show desquamation. These secondary lesions frequently ulcerate and are then highly infectious, but heal after 6 months or more. Secondary yaws affects the skin and bones. The most common bone-related problem is periostitis, an inflammation around the bone, which often occurs in the bones of the fingers and the long bones of the lower arms and legs, causing swollen fingers and limbs. This causes pain at night and thickening of the affected bones (periostitis). About 75% of infected children surveyed in Papua New Guinea reported joint pain. Swollen lymph nodes, fever, and malaise are also common. A latent infection develops after primary and secondary yaws (and possibly, in some cases, without these phases). Within five years (rarely, within ten years), it can relapse and become active again, causing further secondary lesions, which may infect others. These relapse lesions are most commonly found around the armpits, mouth, and anus.
Being one of the biggest donors to the WHO, the country's unpaid fees of estimated $260 million has already caused massive job losses at the organization. However, as a response, Washington said they saw no reason to comply. Ronald G. Nahass, president of the Infectious Diseases Society of America (IDSA), criticized the withdrawal, calling it "a shortsighted and misguided abandonment of our global health commitments" and "scientifically reckless". He emphasized that "It fails to acknowledge the fundamental natural history of infectious diseases" and that "Global cooperation and communication are critical to keep our own citizens protected because germs do not respect borders," adding that global cooperation is "not a luxury" but a "biological necessity".
== Functions == Vernix appears in all full-term infants, with widely varying body coverage. Premature and post-mature births generally do not display any. It is theorized (and observed) to serve several purposes:
Sources: en.wikipedia.org
The enzyme characterised from Escherichia coli combines adenosine triphosphate and nicotinate mononucleotide to give deamido-NAD, a precursor to the coenzyme, nicotinamide adenine dinucleotide (NAD). Pyrophosphate (PPi) is a byproduct. In organisms which use this biosynthetic pathway to NAD, the final step is an amidation reaction. This enzyme belongs to the family of transferases, specifically those transferring phosphorus-containing nucleotide groups (nucleotidyltransferases). The systematic name of this enzyme class is ATP:nicotinate-ribonucleotide adenylyltransferase. Other names in common use include deamido-NAD+ pyrophosphorylase, nicotinate mononucleotide adenylyltransferase, deamidonicotinamide adenine dinucleotide pyrophosphorylase, NaMN-ATase, and nicotinic acid mononucleotide adenylyltransferase.
transcriptional bursting The intermittent nature of transcription and translation mechanisms. Both processes occur in "bursts" or "pulses", with periods of gene activity separated by irregular intervals.
SWCNTs have found use in long lasting, faster charged lithium ion batteries; polyamide car parts for e-painting; automotive primers for cost benefits and better aesthetics of topcoats; ESD floors; electrically conductive lining coatings for tanks and pipes; rubber parts with improved heat and oil aging stability; conductive gelcoats for ATEX requirements and tooling conductive gelcoats for increased safety and efficiency; and heating fiber coatings for infrastructure elements.
Sources: en.wikipedia.org
Isothermal titration calorimetry (ITC), is considered as the most quantitative technique available for measuring the thermodynamic properties of protein–protein interactions and is becoming a necessary tool for protein–protein complex structural studies. This technique relies upon the accurate measurement of heat changes that follow the interaction of protein molecules in solution, without the need to label or immobilize the binding partners, since the absorption or production of heat is an intrinsic property of virtually all biochemical reactions. ITC provides information regarding the stoichiometry, enthalpy, entropy, and binding kinetics between two interacting proteins. Microscale thermophoresis (MST), is a new method that enables the quantitative analysis of molecular interactions in solution at the microliter scale. The technique is based on the thermophoresis of molecules, which provides information about molecule size, charge and hydration shell. Since at least one of these parameters is typically affected upon binding, the method can be used for the analysis of each kind of biomolecular interaction or modification. The method works equally well in standard buffers and biological liquids like blood or cell-lysate. It is a free solution method which does not need to immobilize the binding partners. MST provides information regarding the binding affinity, stoichiometry, competition and enthalpy of two or more interacting proteins.
A mixer-settler consists of a mixing stage that often forms a suspension of two immiscible liquids followed by a settling stage that allows the liquids to separate into two layers by gravity. Mixer-settlers are typically used when a process requires longer residence times and when the solutions are easily separated by gravity. In a multistage countercurrent process, multiple mixer-settlers are installed in series with the settled output of one stage being fed to subsequent stages for further separation.
=== 1990 === 5 August The Nuts and Bolts of Ben Bowlby, 23 year old Ben Bowlby; his sister Sophie studied costume design; his father was a photographer at the Royal Free Hospital; the first fifteen minutes would be shown as part of the November 1991 episode; monocoque structures; his child psychiatrist grandfather John Bowlby, the son of Sir Anthony Bowlby; Frank Dernie at Team Lotus in Norfolk, and automotive diffusers; circuits at Snetterton Circuit. Narrated by Martin Jarvis, directed by Patrick Uden, made by Uden Associates 12 August The Greenhouse Conspiracy 19 August Selling the Secret, about the Soviet Union selling technology; it visited the Khrunichev State Research and Production Space Center in Moscow. Produced by Paul Murricane, directed by Ross Wilson, made by Scottish Television 2 September Blue Skies, about British innovation and its funding; biologist Nigel R.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.